RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Net Income

Bottom-line profit, the starting point for calculating cash from operations.

RxSight, Inc.NASDAQ: RXST

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $15.88M (cash outflow) rose 93.9% year over year, ahead of the +75.7% change in trailing-twelve-month net income. Sequentially, it rose 73.6% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.

Context

  • Net income amounted to 29.0% of revenue in FY2025, up 9.3 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$6.75M (-82.7%) for the fiscal year ending Dec 2026, a slowdown from the +41.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$15.88M+73.6% QoQ
Last fiscal yearDec 2025
-$38.94M+41.8% YoY
LTMMar 2026
-$46.64M+75.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.9%+16.5%-77.4 pp
1 year+41.8%-82.7%-124.5 pp
3-year CAGR-16.4%-2.0%+14.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(38.94M) USD
Year-over-year change
-41.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 net income of $46.64M is the 3rd largest of the 9 companies compared; the peer median is $28.33M.
  • Its year-over-year change of +75.7% is the 2nd highest of 9, against a peer median of +16.2%.
  • Net income amounts to 36.6% of revenue for RXST, versus a peer median of 16.3%.
RXST Competitors Peer median
Net Income for RXST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BFLYButterfly Network, Inc.LTM Mar 2026$75.77M +17.1%-23.0%73.6%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$61.04M +15.2%+11.3%29.4%
RXSTRxSight, Inc.LTM Mar 2026$46.64M +75.7%-16.4%36.6%
KIDSOrthoPediatrics Corp.LTM Mar 2026$39.68M -2.5%—16.3%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$35.1M +30.0%+33.8%—
NPCENeuroPace, Inc.LTM Mar 2026$21.57M -13.1%-23.0%21.7%
TCMDTactile Systems Technology, Inc.LTM Mar 2026$20.3M +25.3%—5.9%
CERSCerus CorporationLTM Mar 2026$9.56M -49.7%-28.5%4.3%
DCTHDelcath Systems, Inc.LTM Mar 2026$561K +103.9%—0.6%
Peer median (excluding RXST) $28.33M+16.2%-23.0%16.3%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Depreciation & Amortization3.99M4.02M4.24M3.62M3.27M
Deferred Income Tax(5.4M)0000
Stock-Based Compensation7.58M11.4M15.75M24.64M31.61M
Change in Working Capital(2.68M)(7.41M)(9.07M)(9.21M)(4.89M)
Accounts Receivables(2M)(6.09M)(9.33M)(9.8M)6.66M
Inventory(2.11M)(7.56M)(2.75M)(4.99M)(11.48M)
Accounts Payables555K635K1.25M946K627K
Other Working Capital874K5.6M1.75M4.64M(692K)
Other Non-Cash Items493K(101K)(3.9M)(8.54M)(6.55M)
Operating Cash Flow(44.71M)(58.85M)(41.59M)(16.95M)(15.51M)
Capital Expenditures(1.94M)(2.39M)(4.81M)(5.44M)(3.83M)
Acquisitions (Net)79.97M(42.34M)17.32M00
Purchases of Investments(159.97M)(212.66M)(272.32M)(336.87M)(239.28M)
Sales of Investments80M255M255M243M260M
Other Investing Activities(79.97M)42.34M(17.32M)00
Investing Cash Flow(81.91M)39.95M(22.13M)(99.31M)16.89M
Debt Repayment14.97M(121K)(40.15M)(61K)(26K)
Common Stock Issued121.14M7.83M105.96M128.92M3.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.23M(1.38M)(4.28M)(5.54M)(2.06M)
Financing Cash Flow137.34M6.33M61.52M123.32M1.86M
Effect of Forex Changes(10K)(9K)6K(9K)2K
Net Change in Cash10.72M(12.58M)(2.19M)7.05M3.24M
Free Cash Flow(46.65M)(61.24M)(46.41M)(22.39M)(19.34M)

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.